SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.530
+0.060 (1.73%)
At close: Apr 28, 2026, 4:00 PM EDT
3.500
-0.030 (-0.85%)
After-hours: Apr 28, 2026, 6:20 PM EDT
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Samuel Reich |
Contact Details
Address: 777 W 41st St. Miami Beach, Florida 33140 United States | |
| Phone | 305 845 2813 |
| Website | sab.bio |
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T103 |
| ISIN Number | US78397T2024 |
| Employer ID | 85-3899721 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | Chief Executive Officer and Director |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
| Lucy To | Executive Vice President and Chief Financial Officer |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Cristi Barnett | Vice President of Investor Relations and Corporate Communications |
| Catherine DeRose | Vice President of Human Resources |
| Hua Wu Ph.D. | Senior Vice President of Product Development |
| Dr. Carlos N. Carillo M.Sc., Ph.D. | Senior Vice President of Regulatory Affairs |
| Angie Parizek | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 8-K | Current Report |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | SCHEDULE 13D/A | Filing |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 424B5 | Filing |
| Mar 17, 2026 | 424B5 | Filing |
| Mar 11, 2026 | SCHEDULE 13D/A | Filing |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |